Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Respiratory Journal Année : 2017

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

1 Service de pneumologie [Toulouse]
2 CHU Tenon [AP-HP]
3 SU - Sorbonne Université
4 UPMC - Université Pierre et Marie Curie - Paris 6
5 Bureau des Essais Cliniques - Cellule Biostatistique [IUCT Oncopole, Toulouse]
6 Service Dermatologie [CHU Toulouse]
7 Service d’oncologie thoracique et essais précoces [CHU Bichat]
8 Département d'oncologie thoracique [CHU Grenoble]
9 Département d'hématologie [Gustave Roussy]
10 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
11 Département d'oncologie médicale [Saint Herblain]
12 CRCINA-ÉQUIPE 9 - Apoptosis and Tumor Progression
13 Service de pneumologie [Centre Hospitalier Lyon Sud - HCL]
14 Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen]
15 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle
16 Service de Pneumologie [Suresne]
17 Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
18 Département de Cancérologie Générale [Lille]
19 Département de Cancérologie Médicale [Lyon]
20 Service de Pneumologie [CHRU Tours]
21 Medical Oncology Department [Luzern, Switzerland]
22 Medical Oncology Department [St Gallen, Switzerland]
23 Département d'oncologie médicale [Centre Georges-François Leclerc]
24 Service de Pneumonologie [Toulon]
25 Service de Pneumologie Aiguë Spécialisée et Cancérologie Thoracique [HCL Lyon]
26 EA3738 - Ciblage thérapeutique en Oncologie
27 Service de Dermatologie [HCL, Lyon]
28 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
29 Service de Dermatologie [CHU de Grenoble site Nord]
30 Service de radiologie
David Planchard
  • Fonction : Auteur

Résumé

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-01819272 , version 1 (20-06-2018)

Identifiants

Citer

Myriam Delaunay, Jacques Cadranel, Amélie Lusque, Nicolas Meyer, Valérie Gounaut, et al.. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal, 2017, 50 (5), ⟨10.1183/13993003.00050-2017⟩. ⟨inserm-01819272⟩
295 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More